Continuation of funding for systemic anti-cancer therapy following a break in treatment

Document first published:
Page updated:
Topic:
,
Publication type:

The various different types of cancer medicines and treatments are collectively termed systemic anti-cancer therapies (SACT).

The policy information here outlines how funding for SACT can continue following a patient’s break in treatment. Such a break may be to allow for recovery from drug-related side effects, interruptions to treatment due to surgery and/or radiotherapy, treatment for a new illness, medical emergencies unrelated to the cancer, etc.

Link

Continuation of funding for systemic anti-cancer therapy following a break in treatment

Continuation of funding for systemic anti-cancer therapy following a break in treatment

NHS England is not responsible for content on external websites.

Summary

Main policy guidance document.

Accessible webpage.

Published 16 June 2023.

Link

Engagement report: SACT treatment break

Engagement report: SACT treatment break

NHS England is not responsible for content on external websites.

Summary

Feedback received by NHS England from engagement during the development of this policy, and how this feedback has been considered

Accessible webpage.

Published 16 June 2023.

Link

SACT treatment break equality and health inequalities impact assessment (EHIA)

SACT treatment break equality and health inequalities impact assessment (EHIA)

NHS England is not responsible for content on external websites.

Summary

Equality and health inequalities impact assessment (EHIA) for this guidance.

Accessible webpage.

Published 16 June 2023.